Arthneeti
All Q2 FY26 results →
AL

Abbott Laboratories

Q2 FY26Health Care Equipment and Supplies

Abbott Laboratories Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹86
Market cap₹1.5L Cr
P/E24.3
Updated29 May 2026
Read3 min read

What the Q2 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

The short version

- Core Lab business expected to grow at a mid-single-digit rate full-year, with stronger growth in the second half of the year due to stabilizing China VBP impact and continued strength in U.S., Europe, and Latin America. - Abbott expects an acceleration in growth in the second half of 2026, driven by key business segments and new product launches.

From Abbott Laboratories's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth
  • Core Lab business expected to grow at a mid-single-digit rate full-year, with stronger growth in the second half of the year due to stabilizing China VBP impact and continued strength in U.S., Europe, and Latin America.
  • U.S. Core Lab contracts have high renewal rates (90%+) and share gains with win rates over 55%.
  • Nutrition business is showing early signs of volume recovery following targeted price reductions and expects growth to return in the back half through product launches and distribution expansion.
  • Continuous Glucose Monitoring (CGM) market is poised for acceleration; double-digit growth expected from Q2 onward, driven by reimbursement expansions including upcoming type 2 non-insulin coverage.

2 more points from Abbott Laboratories's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Abbott Laboratories said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
There are some relevant strategic initiatives and investments implied: - Continued product launches and portfolio expansions across various divisions, including EP business (e.g., Volt catheters, second-generation LAA device). - Investments in clinical trials and limited market releases to refine product positioning and execution (e.g., Volt and Tactiflex catheter launches). - Focus on broadening geographic and product coverage, including expanding diagnostics and Nutrition business. - Strategic move of left atrial appendage closure (LAAC) devices into electrophysiology to better accelerate growth.

2 more points from Abbott Laboratories's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Abbott Laboratories said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Abbott Laboratories said on order book & pipeline — free account, 30 seconds.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Abbott Laboratories and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Abbott Laboratories Q2 FY26 results?

- Core Lab business expected to grow at a mid-single-digit rate full-year, with stronger growth in the second half of the year due to stabilizing China VBP impact and continued strength in U.S., Europe, and Latin America. - Abbott expects an acceleration in growth in the second half of 2026, driven by key business segments and new product launches.

What is Abbott Laboratories share price analysis?

Abbott Laboratories currently shows a below-average growth signal. The stock trades at a P/E of 24.3 with a market cap of $150,318. Investors should review the full earnings analysis for detailed insights.

Keep Abbott Laboratories on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.